Scientific program

Where diagnostic delay happens, what the referral pattern looks like, and what this meeting sets out to change.

Cutaneous presentations, which assay answers which question, and where treatment has moved.

Direct immunofluorescence, serology, and sequencing treatment in pemphigus and pemphigoid.

Discoid, subacute and tumid disease, and when cutaneous findings change systemic workup.

Myositis-specific antibodies, amyopathic presentations, and the screening interval question.

Localised versus systemic disease, and what the skin score is actually measuring.

Tryptase interpretation, when to biopsy marrow, and managing mediator symptoms.

Distinguishing GPP from plaque disease under pressure, and the current therapeutic pathway.

Where medical therapy stops, where surgical planning starts, and how to run both together.

Selecting patients, monitoring, and setting expectations on regrowth timelines.

Topical and phototherapy combinations, stability assessment, and relapse prevention.

Genodermatoses that reach general dermatology first, and how to route them.

Genotype-directed treatment, biomarker selection, and what is realistically close to clinic.

Case-based review of the referral patterns that delay diagnosis in rare dermatologic disease.

Convened and organized by the supporting company. Attendance is by invitation from the organizing company.

Convened and organized by the supporting company. Attendance is by invitation from the organizing company.